AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 161 min read$INCY

Incyte Genomics Inc (INCY) EPS 2025: $6.41, up 4173.3%

Incyte Genomics Inc (INCY) reported $6.41 diluted EPS for FY2025, up 4173.3% YoY. Trailing 12-month EPS is $7.08. Q1 FY2026 EPS was $1.47, up 83.7% YoY. Data sourced from SEC filings.

Original reporting
stocktitan.net
Published Sep 16, 2026, 3:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 5:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$INCY
Bullish
high confidence
Mentioned
$INCY
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$INCYBullishHigh
01

Why it matters

The earnings surprise could lead to a rapid revaluation of the stock, prompting short‑covering and new buying.

02

Market read

First disclosure of a massive earnings increase for a mid‑cap biotech, likely to move the stock.

03

What to watch

Potential accounting adjustments or one‑time gains could be driving the surge.

Relevance 8/10Novelty 8/10Timing: post‑FY2025 earnings release

Background

The article presents raw EPS figures from Incyte Genomics' SEC filings for FY2025 and the latest quarter.

Company-level read

Ticker impact

$INCYBullishHigh confidence
Context

Incyte Genomics reported FY2025 diluted EPS of $6.41, a 4173.3% YoY increase, and $7.08 over the trailing twelve months.

Expected impact

Potential upside as investors re‑price the stock on the unexpected earnings jump.

Evidence & confidence

First‑time disclosure of FY2025 results with extreme growth; no prior market pricing of this data.

Market effects

Sector

Biotech sector may see renewed interest as a small‑cap demonstrates outsized earnings growth.

Regional

U.S. biotech investors likely to react; limited broader market effect.

Global

Minimal outside U.S. markets.

Counterpoint

What could challenge this read

The EPS jump may be a one‑off from a non‑recurring event; caution on sustainability.

Key entities

  • company
    Incyte Genomics Inc

    Biopharmaceutical company reporting FY2025 earnings.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 20
$INCYMed

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte (NASDAQ:INCY) projects $4B sales target, with JAKAFI to XR conversion preserving up to $750M. The company advances pipeline, including 989 for myelofibrosis, 734 for pancreatic cancer, and 890 for colorectal cancer. Preclinical data on next-gen therapies to be presented at ASH and ESMO. Povorcitinib for hidradenitis suppurativa and von Willebrand disease treatments also in development.

finance.yahoo.com3 min
AUG 30
$INCYHigh

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks

Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.

yahoo.com2 min
AUG 28
$INCYHighAI 9/10

Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?

Incyte (INCY) and Revolution Medicines (RVMD) are competing in the KRAS inhibitor market. RBC noted INCY's upcoming ESMO data for its KRAS G12D inhibitor, while Bernstein raised RVMD's price target. RVMD received FDA approval for Rasonque. INCY reported Q2 2026 revenue of $1.67B, while RVMD had no product revenue but $3.9B in cash. Institutional investors favor RVMD, with notable holdings by Farallon Capital and Baker Bros. Advisors.

insidermonkey.com3 min